A carregar...

A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)

BACKGROUND: We conducted a phase I dose escalation study to evaluate the safety and immunologic response to peptide immunomodulatory vaccines GL-0810 (HPV16) and GL-0817 (MAGE-A3) in HPV16 and MAGE-A3-positive RM–SCCHN patients, respectively. METHODS: Three dose levels (500, 1,000, and 1,500 µg) of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Immunol Immunother
Main Authors: Zandberg, Dan P., Rollins, Sandra, Goloubeva, Olga, Morales, Robert E., Tan, Ming, Taylor, Rodney, Wolf, Jeffrey S., Schumaker, Lisa M., Cullen, Kevin J., Zimrin, Ann, Ord, Robert, Lubek, Joshua E., Suntharalingam, Mohan, Papadimitriou, John C., Mann, Dean, Strome, Scott E., Edelman, Martin J.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2014
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381442/
https://ncbi.nlm.nih.gov/pubmed/25537079
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-014-1640-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!